论文部分内容阅读
目的 探讨颈动脉加压注射尿激酶治疗缺血性脑梗死的疗效。方法 采用前瞻性多中心随机方案 ,将入选患者随机分为两组 ,颈动脉加压注射尿激酶组 (治疗组 ) 132例 ,常规治疗组 (对照组 ) 89例 ;疗效判定依据1986年中华医学会全国第 2次脑血管病学术会议修订的项目制定。结果 (1)两组疗效比较 ,差异有非常显著性意义 (P <0 0 0 1) ;(2 )治疗开始的时间≤ 48小时与 >48小时者的疗效比较无论是治疗组还是对照组 ,差异均有显著性意义 (P <0 0 0 1) ;(3)对治疗组脑梗死急性期的疗效与恢复期及后遗症期相比差异有显著性意义 (P <0 0 0 5 )。结论 颈动脉加压注射尿激酶治疗缺血性脑梗死 ,提高了缺血区药物浓度 ,克服了全身用药所致的高费用低疗效 ,疗效明显优于常规方法 ,降低了致残率 ,值得临床推广使用。
Objective To investigate the curative effect of carotid artery injection of urokinase on ischemic cerebral infarction. Methods A prospective, multicenter randomized clinical trial was conducted. The patients were randomly divided into two groups: 132 patients received carotid arterial pressure injection of urokinase (treatment group) and 89 patients received conventional therapy (control group) The second National Cerebrovascular Disease Conference revised the project formulation. Results (1) There was a significant difference between the two groups (P <0.01); (2) The therapeutic effect of 48 hours and 48 hours after the start of treatment was no significant difference between the treatment group and the control group (P <0.01). (3) There was significant difference between the treatment group and the recovery and sequelae in the acute stage of cerebral infarction (P <0 05). Conclusion Carotid artery injection of urokinase in the treatment of ischemic cerebral infarction increases the drug concentration in the ischemic area and overcomes the high cost and low curative effect caused by systemic administration. The curative effect is obviously superior to the conventional method, reducing the morbidity and deserving clinical value Promote use.